Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL-Reference-Cited by-同舟云学术

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL

Published:2017-05-05 Issue:5 Volume:12 Page:e0173353
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Alsop Jonathan^ORCID,Medin Jennie,Cornelissen Christian^ORCID,Vormfelde Stefan Viktor^ORCID,Ziemssen Tjalf

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference57 articles.

1. Multiple sclerosis;A Compston;Lancet,2002

2. National MS Society. MS prevalence. Available from: http://www.nationalmssociety.org/About-the-Society/MS-Prevalence.

3. Multiple sclerosis;A Compston;Lancet,2008

4. Clinical relevance of brain volume measures in multiple sclerosis;N De Stefano;CNS drugs,2014

5. Pathology of multiple sclerosis and related inflammatory demyelinating diseases;A Kutzelnigg;Handbook of clinical neurology,2014

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion;Journal of Neurology;2022-05-24

2. Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study;Brain Sciences;2022-02-04

3. Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients;Frontiers in Neurology;2021-03-03

4. Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan;Journal of the Formosan Medical Association;2021-01

5. Correlation between IL-31 and sCD40L plasma levels in Fingolimod-treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS);Journal of Neuroimmunology;2021-01